Adoptive T cell based immunotherapy is gaining significant traction in cancer treatment. Despite its limited efficacy so far in treating solid tumors compared to hematologic cancers, recent advances in T cell engineering render this treatment increasingly more successful in solid tumors, demonstrating its broader therapeutic potential. In this paper we develop a mathematical model to study the efficacy of engineered T cell receptor (TCR) T cell therapy targeting the E7 antigen in cervical cancer cell lines. We consider a dynamical system that follows the population of cancer cells, TCR T cells, and IL-2 treatment concentration. We demonstrate that there exists a TCR T cell dosage window for a successful cancer elimination that can be expressed in terms of the initial tumor size. We obtain the TCR T cell dose for two cervical cancer cell lines: 4050 and CaSki. Finally, a combination therapy of TCR T cell and IL-2 treatment is studied. We show that certain treatment protocols can improve therapy responses in the 4050 cell line, but not in the CaSki cell line.

基于过继T细胞的免疫疗法在癌症治疗中正获得重要的应用。尽管到目前为止，与血液学癌症相比，其在治疗实体瘤方面的疗效有限，但T细胞工程技术的最新进展使这种疗法在实体瘤中变得越来越成功，证明了其更广泛的治疗潜力。在本文中，我们建立了一个数学模型来研究针对E7抗原的工程化T细胞受体（TCR）T细胞疗法在宫颈癌细胞系中的功效。我们考虑一个遵循癌细胞，TCR T细胞和IL-2治疗浓度的动力学系统。我们证明了存在一个TCR T细胞剂量窗口可以成功消除癌症，可以根据初始肿瘤大小来表达。我们获得了两种宫颈癌细胞系的TCR T细胞剂量：4050和CaSki。最后，研究了TCR T细胞和IL-2治疗的联合治疗。我们显示某些治疗方案可以改善4050细胞系中的治疗反应，但不能改善CaSki细胞系中的治疗反应。